2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 507

Echocardiographic Markers of Right Ventricle Dysfunction in Hispanic Patients with Rheumatoid Arthritis: A Case-Control Study

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 702

Effect of Biologics on Radiographic Progression of Peripheral Joints in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 419

Effect of Changes in Physical Activity on Cartilage Degradation in Knee Osteoarthritis

Orthopedics, Low Back Pain and Rehabilitation Poster – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 578

Effect of Disease Duration and Other Patient Baseline Characteristics on Outcomes in Tocilizumab-Treated Rheumatoid Arthritis Patients: A Pooled Analysis

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 456

Effect of Local and Systemic CCR2 Blockade on Knee Hyperalgesia in a Mouse Model of Osteoarthritis

Pain Mechanisms – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 347

Effectiveness of a Biopsychosocial Exercise Approach in Rheumatic Diseases

Measures and Measurements of Healthcare Quality Poster – ARHP

9:00AM-11:00AM: Abstract Number: 181

Effectiveness of Elective Completion in Enhancing Board Preparedness and Comfort with Diagnosing and Treating Rheumatologic Conditions in a Cohort of Internal Medicine Residents at an Academic Medical Center

Education Poster

9:00AM-11:00AM: Abstract Number: 586

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World DATA from the ST. Gallen and-Aarau RA-Cohort

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 454

Effects of Prolonged Chemogenetic Inhibition of Nociceptors in a Murine Surgical Model of Osteoarthritis

Pain Mechanisms – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 517

Effects of Statin-Treatment on Coronary Plaques in Patients with Inflammatory Joint Diseases

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 422

Efficacy and Safety of a Fixed-Dose Combination of Nimesulide/Pantoprazole Compared with Naproxen/Esomeprazole for Pain Relief in Patients with Osteoarticular Diseases and Dyspeptic Symptoms

Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 563

Efficacy and Safety of Abatacept in Combination with MTX in Early, MTX-Naïve, Anti-Citrullinated Protein Antibody–Positive Patients with RA: Primary and 1-Year Results from a Phase IIIb Study

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 696

Efficacy and Safety of Novel Targeted Synthetic DMARD and Biological DMARD in Active Psoriatic Arthritis: A Systematic Review, Meta-Analysis, and Network Meta-Analysis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 620

Efficacy of a Second Tumor Necrosis Factor Inhibitor (TNFi) in the Treatment of Rheumatoid Arthritis (RA)

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 684

Efficacy of Ixekizumab in Different Phenotypes of Patients with Active Psoriatic Arthritis (PsA): Results from the Spirit Trials

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].